Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Equity Ratio (2018 - 2025)

BioNexus Gene Lab's Equity Ratio history spans 8 years, with the latest figure at 0.89 for Q3 2025.

  • For Q3 2025, Equity Ratio rose 4.75% year-over-year to 0.89; the TTM value through Sep 2025 reached 0.89, up 4.75%, while the annual FY2024 figure was 0.8, 5.85% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.89 at BioNexus Gene Lab, up from 0.8 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.89 in Q3 2025 and bottomed at 0.69 in Q1 2021.
  • The 5-year median for Equity Ratio is 0.8 (2025), against an average of 0.79.
  • The largest annual shift saw Equity Ratio crashed 89.05% in 2021 before it grew 21.04% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.75 in 2021, then increased by 1.69% to 0.76 in 2022, then increased by 11.1% to 0.85 in 2023, then fell by 5.85% to 0.8 in 2024, then grew by 12.12% to 0.89 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Equity Ratio are 0.89 (Q3 2025), 0.8 (Q2 2025), and 0.82 (Q1 2025).